P-088 The Management of Recalcitrant Infliximab Reactions Utilizing a Modified Antibody-Clearing Infusion Protocol
نویسندگان
چکیده
منابع مشابه
Infliximab-Related Infusion Reactions: Systematic Review
OBJECTIVE Administration of infliximab is associated with a well-recognised risk of infusion reactions. Lack of a mechanism-based rationale for their prevention, and absence of adequate and well-controlled studies, has led to the use of diverse empirical administration protocols. The aim of this study is to perform a systematic review of the evidence behind the strategies for preventing infusio...
متن کاملa study on construction of iranian life tables: the case study of modified brass logit system
چکیده ندارد.
15 صفحه اولInfusion-related reactions to Rituximab: pathogenic mechanism and proposal of a new modified desensitization protocol
Background Rituximab is a chimeric monoclonal antibody against the surface protein CD20 of B cells, used in the treatment of hematologic malignances and autoimmune diseases. Some patients develop hypersensitivity reactions after the infusion. It is unknown the percentage of these which are due to an IgE allergic mechanism. Also, there is not a standardized desensitization protocol that allows u...
متن کاملThe Journal of Rheumatology Prospective Real-world Community Registry Incidence and Management of Infusion Reactions to Infliximab in a
Objective. Infliximab (IFX) is a therapeutic monoclonal antibody targeting tumor necrosis factor-a indicated in the treatment of chronic inflammatory diseases. IFX is administered by intravenous infusion and may be associated with different types of infusion reactions. Methods. RemiTRAC Infusion (NCT00723905) is a Canadian observational registry in which patients receiving IFX are followed pros...
متن کاملInfliximab in recalcitrant generalized pustular arthropatic psoriasis.
Generalized pustular psoriasis is an unstable inflammatory type of psoriasis, with widespread areas of erythema and sterile pustules, associated with fever and systemic symptoms. Infliximab is a monoclonal antibody with anti-TNFalpha activity, approved for use in psoriasis. We describe a male patient with a long history of stable arthropathic psoriasis, hospitalized with a generalized pustular ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Inflammatory Bowel Diseases
سال: 2014
ISSN: 1078-0998
DOI: 10.1097/01.mib.0000456827.53643.50